The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind’s MEAI VANCOUVER, Aug. 24, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“ Clearmind” or the “company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health…


Previous articleAlgernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
Next articleBetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects